Search

Author/Creator Altendorfer, Mario

1. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. (3rd August 2017)

Authors:
Hettema, Willem; Wynne, Christopher; Lang, Benjamin; Altendorfer, Mario; Czeloth, Niklas; Lohmann, Ragna; Athalye, Sandeep; Schliephake, Dorothee
Journal:
Expert opinion on investigational drugs
Issue:
Volume 26:Number 8(2017)
Page Start:
889
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. (1st December 2016)

Authors:
Wynne, Christopher; Altendorfer, Mario; Sonderegger, Ivo; Gheyle, Lien; Ellis-Pegler, Rod; Buschke, Susanne; Lang, Benjamin; Assudani, Deepak; Athalye, Sandeep; Czeloth, Niklas
Journal:
Expert opinion on investigational drugs
Issue:
Volume 25:Number 12(2016:Dec.)
Page Start:
1361
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗